Captrust Financial Advisors Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Captrust Financial Advisors grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,862 shares of the biopharmaceutical company's stock after purchasing an additional 5,829 shares during the period. Captrust Financial Advisors' holdings in Halozyme Therapeutics were worth $1,428,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $69,000. Shaker Investments LLC OH grew its position in shares of Halozyme Therapeutics by 12.3% during the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company's stock valued at $3,601,000 after purchasing an additional 8,249 shares in the last quarter. Foster & Motley Inc. lifted its holdings in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock worth $1,113,000 after acquiring an additional 12,630 shares during the last quarter. Jennison Associates LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth $731,000. Finally, Koa Wealth Management LLC lifted its holdings in shares of Halozyme Therapeutics by 10.6% during the 4th quarter. Koa Wealth Management LLC now owns 82,407 shares of the biopharmaceutical company's stock worth $3,940,000 after acquiring an additional 7,924 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This represents a 12.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. This trade represents a 5.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,697 shares of company stock valued at $1,276,552. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Up 2.4%

Halozyme Therapeutics stock traded up $1.27 during mid-day trading on Monday, hitting $53.29. The company's stock had a trading volume of 2,227,461 shares, compared to its average volume of 1,606,448. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of 15.54, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. The business has a 50 day moving average price of $60.54 and a 200-day moving average price of $55.95. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm's revenue for the quarter was up 35.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.79 earnings per share. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on HALO shares. HC Wainwright reaffirmed a "buy" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Finally, Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective for the company. in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $61.90.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.